Johnson & Johnson (NYSE:JNJ) Holdings Increased by Insight Folios Inc

Insight Folios Inc lifted its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 6.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,566 shares of the company’s stock after buying an additional 2,122 shares during the quarter. Johnson & Johnson makes up 3.0% of Insight Folios Inc’s holdings, making the stock its 9th largest position. Insight Folios Inc’s holdings in Johnson & Johnson were worth $6,313,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Family CFO Inc purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth about $26,000. RE Dickinson Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after buying an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC boosted its stake in shares of Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after buying an additional 120 shares during the last quarter. Professional Financial Advisors LLC boosted its stake in shares of Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares during the last quarter. Finally, Joseph P. Lucia & Associates LLC acquired a new position in Johnson & Johnson in the 1st quarter worth about $38,000. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on JNJ. Wells Fargo & Company upped their price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Citigroup reduced their target price on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Morgan Stanley dropped their price target on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a research report on Monday, September 12th. Daiwa Capital Markets started coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating for the company. Finally, UBS Group dropped their price target on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $189.78.

Johnson & Johnson Trading Up 1.8 %

Shares of Johnson & Johnson stock opened at $166.18 on Friday. The firm has a market capitalization of $436.92 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 2.95 and a beta of 0.61. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. The stock has a 50 day moving average of $168.06 and a 200 day moving average of $174.12.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.48 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 10.7 earnings per share for the current year.

Johnson & Johnson declared that its board has approved a stock repurchase program on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to purchase up to 1.2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were given a dividend of $1.13 per share. The ex-dividend date was Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.72%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.